HCW Biologics Inc

NASDAQ HCWB

Data sourced from

and

Download Data

HCW Biologics Inc Days Sales Outstanding (DSO) 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -21.85%

HCW Biologics Inc Days Sales Outstanding (DSO) 2 year CAGR is -21.85% for the Trailing 12 Months (TTM) ending March 31, 2024. The days sales outstanding ratio measures the average number of days it takes for a company to collect payment from its customers. It is calculated by dividing receivables by revenue and then multiplying by 365. This ratio indicates the average collection period for accounts receivable and provides insights into the effectiveness of the company's credit and collection policies. A shorter period indicates faster collection and better cash flow management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

HCW Biologics Inc Days Sales Outstanding (DSO) for the Trailing 12 Months (TTM) ending December 31, 2022 was 132.26.
HCW Biologics Inc Days Sales Outstanding (DSO) for the Trailing 12 Months (TTM) ending December 31, 2020 was 222.57.

NASDAQ: HCWB

HCW Biologics Inc

CEO	Dr. Hing C. Wong Ph.D.
IPO Date	July 20, 2021
Location	United States
Headquarters	2929 North Commerce Parkway, Miramar, FL, United States, 33025
Employees	45
Sector	Healthcare
Industry	Biotechnology

Description

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Key trends